BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol 2015; 21(48): 13548-13554 [PMID: 26730167 DOI: 10.3748/wjg.v21.i48.13548]
URL: https://www.wjgnet.com/1007-9327/full/v21/i48/13548.htm
Number Citing Articles
1
Shoko Ono, Mototsugu Kato, Soichi Nakagawa, Katsuhiro Mabe, Naoya Sakamoto. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillinHelicobacter 2017; 22(3) doi: 10.1111/hel.12374
2
James P. Franciosi, Edward B. Mougey, Andre Williams, Roberto A. Gomez‐Suarez, Cameron Thomas, Christa L. Creech, Katherine George, Diana Corao, John J. Lima. Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal RefluxThe Journal of Clinical Pharmacology 2018; 58(1): 89 doi: 10.1002/jcph.977
3
Juan Fu, Chang-Feng Sun, Hong-Yan He, Suvash Chandra Ojha, Han Shi, Cun-Liang Deng, Yun-Jian Sheng. The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysisPharmacogenomics 2021; 22(13): 859 doi: 10.2217/pgs-2020-0127
4
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang. A Review of the Novel Application and Potential Adverse Effects of Proton Pump InhibitorsAdvances in Therapy 2017; 34(5): 1070 doi: 10.1007/s12325-017-0532-9
5
Yuehua Gong, Yuan Yuan. Resistance mechanisms of Helicobacter pylori and its dual target precise therapyCritical Reviews in Microbiology 2018; 44(3): 371 doi: 10.1080/1040841X.2017.1418285
6
Ju Yup Lee. Helicobacter pylori2023; : 607 doi: 10.1007/978-981-97-0013-4_51
7
Yoen‐Young Chuah, Deng‐Chyang Wu, Seng‐Kee Chuah, Jyh‐Chin Yang, Tzong‐Hsi Lee, Hong‐Zen Yeh, Chan‐Lin Chen, Yu‐Hwa Liu, Ping‐I Hsu. Real‐world practice and Expectation of Asia‐Pacific physicians and patients in Helicobacter Pylori eradication (REAP‐HP Survey)Helicobacter 2017; 22(3) doi: 10.1111/hel.12380
8
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapyJournal of Antimicrobial Chemotherapy 2019; 74(1): 11 doi: 10.1093/jac/dky401
9
Muhamad A. K. Shakhatreh, Omar F. Khabour, Karem H. Alzoubi, Mohammed N. BaniHani, Ahmed Abu-Siniyeh, Nabil A. Bashir, Salsabeel H. Sabi, Mahmoud Mahafdah. <p>The Influence of <em>IL-1B</em> Gene Polymorphisms on <em>H. pylori</em> Infection and Triple Treatment Response Among Jordanian Population</p>The Application of Clinical Genetics 2020; : 139 doi: 10.2147/TACG.S253778
10
Komei Iwai, Tetsuji Azuma, Takatoshi Yonenaga, Yasuyuki Sasai, Kazutoshi Watanabe, Akihiro Obora, Fumiko Deguchi, Takao Kojima, Takaaki Tomofuji. Association between failed eradication of 7-day triple therapy for Helicobacter pylori and untreated dental caries in Japanese adultsScientific Reports 2024; 14(1) doi: 10.1038/s41598-024-54757-8
11
Kazutake Oguma, Masashi Sato, Sadanori Kubo, Hiroaki Shiraish, Takeshi Yano, Shigeaki Aihara, Masaaki Matsukawa, Kazuhide Kumagai. A study of symptoms, eradication rates, and the degree of atrophy in patients with Helicobacter pylori-associated gastritisProgress of Digestive Endoscopy 2018; 92(1): 50 doi: 10.11641/pde.92.1_50
12
Joon Sung Kim, Weonjin Ko, Jun‐Won Chung, Tae Ho Kim. Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled studyHelicobacter 2023; 28(3) doi: 10.1111/hel.12977
13
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysisGene Reports 2021; 25: 101340 doi: 10.1016/j.genrep.2021.101340
14
Gwang Ha Kim. Status ofHelicobacter pyloriEradication in JapanThe Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017; 17(1): 4 doi: 10.7704/kjhugr.2017.17.1.4
15
Nihal El Rouby, John J. Lima, Julie A. Johnson. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicineExpert Opinion on Drug Metabolism & Toxicology 2018; 14(4): 447 doi: 10.1080/17425255.2018.1461835
16
Dana M. Harris, Fernando F. Stancampiano, M. Caroline Burton, Ann M. Moyer, Michael J. Schuh, Jose R. Valery, Yan Bi. Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical PracticeDigestive Diseases and Sciences 2021; 66(12): 4120 doi: 10.1007/s10620-020-06814-1
17
Kazutake Oguma, Sadanori Kubo, Fumihiko Nozu, Hiroaki Shiraishi, Takeshi Yano, Shigeaki Aihara, Masaaki Matsukawa, Kazuhide Kumagai. A study of digestive symptoms before and after successful Helicobacter pylori eradication therapyProgress of Digestive Endoscopy 2017; 91(1): 52 doi: 10.11641/pde.91.1_52
18
Paulius Jonaitis, Laimas Jonaitis, Juozas Kupcinskas. Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Helicobacter pylori Eradication RegimensCurrent Drug Metabolism 2020; 21(11): 830 doi: 10.2174/1389200221666200514081442
19
Hyeonsoo Park, Choon Ok Kim, Mikyung Kim, Yeji Lim, Woo Yul Lee, Sukyong Yoon, Min Soo Park. Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjectsTranslational and Clinical Pharmacology 2020; 28(3): 136 doi: 10.12793/tcp.2020.28.e16
20
Na‐Yun Su, Qing Shi, Hao Mei, Jie Hu, Yu‐Xiang Liu, Han‐Ning Liu, Heng‐Qi Liu, Yan Guo, Xing‐wei Wang, Chun‐Hui Lan. Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysisHelicobacter 2023; 28(5) doi: 10.1111/hel.13003
21
Mohammed N. BaniHani, Omar F. Khabour, Karem H. Alzoubi, Nabil A. Bashir, Muhamad Ali K. Shakhatreh, Salsabeel H. Sabi, Nasr Alrabadi. The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among JordaniansGenes 2020; 11(1): 63 doi: 10.3390/genes11010063
22
Yoshimasa Saito, Kaho Konno, Moeka Sato, Masaru Nakano, Yukako Kato, Hidetsugu Saito, Hiroshi Serizawa. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pyloriCancers 2019; 11(1): 116 doi: 10.3390/cancers11010116
23
William D. Chey, Francis Mégraud, Loren Laine, Luis J. López, Barbara J. Hunt, Colin W. Howden. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical TrialGastroenterology 2022; 163(3): 608 doi: 10.1053/j.gastro.2022.05.055
24
Byeong Yun Ahn, Soo-Jeong Cho. Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori EradicationThe Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(3): 174 doi: 10.7704/kjhugr.2023.0041